I suspect the company will provide follow up commentary either today or Monday to affirm/clarify/correct the PR'd and CTAD numbers. At some point we'll certainly be getting more tables, and time study charts.
I'm glad we were able to present at CTAD. Unfortunately, instead of favorable ADAS-Cog comparison to Lecanemab, the main narrative coming out is "positive but incomplete and possibly erroneous data". That can be remediated. Let's see.
Market Data 
Markets 
AI
